Chasing Amgen on KRAS combo, Roche dishes out $75M for Relay's SHP2 drug to pair with in-house program
With Amgen’s KRAS drug poised to cross the finish line, it’s no longer enough for its Big Pharma brethren to just have their own …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
